Interesting MRNA Put And Call Options For March 27th

Moderna (MRNA) is profiled with two option strategies: selling a $42 put (bid $3.20) which nets a $38.80 cost basis vs. the $42.31 stock price, is ~1% OTM, has a 59% probability of expiring worthless and would yield 7.62% (55.67% annualized) on cash commitment; and selling a $44 covered call (bid $3.35) against shares bought at $42.31, which is ~4% OTM, would produce an 11.91% total return if called at the March 27 expiration and has a 46% chance of expiring worthless, representing a 7.92% (57.85% annualized) YieldBoost. Implied volatilities are elevated (put 90%, call 94%) versus trailing 12-month volatility of 66%, making option premiums rich and attractive to yield-seeking option sellers while capping upside for equity holders.

Analysis

Market structure: Option-implied vol for MRNA (puts 90%, calls 94%) sits materially above realized 66%, creating a rich premium surface for short-dated sellers. Short-dated premium (Mar 27) priced at ~7.6–7.9% yield on cash committed implies options market expects elevated event risk or skewed downside; beneficiaries are premium sellers and market-makers collecting theta, losers are directional buyers and long-vol speculators. Cross-asset: a large IV re-pricing in biotech would raise equity risk premia, widen credit spreads for high-beta pharma names, and push flows into safer FX (USD) and gold in stress episodes.

Risk assessment: Tail risks include clinical/trial failure, sudden vaccine demand drop, or regulatory action that can gap MRNA >30% (low-probability but high-impact). Immediate (days): theta decay favors sellers; short-term (weeks/months): event catalysts (earnings, readouts) can spike IV >150%; long-term (quarters/years): revenue concentration and product lifecycle determine valuation. Hidden dependencies: revenue sensitivity to seasonal COVID demand and government procurement; second-order risk is forced deleveraging of option sellers on large gaps.

Trade implications: Tactical plays favor defined-risk option selling: cash-secured 42 puts (Mar 27) or 42/38 put spreads to collect rich premium while capping downside; covered-call 44 (Mar 27) is attractive for holders willing to cap upside at ~12% through expiry. Size trades modestly (1–3% portfolio per strategy), avoid naked shorts >3% AUM, and prefer near-term expiry where IV>realized. Monitor IV skew, roll cost, and close/hedge ahead of known catalysts within 7–10 days.

Contrarian angles: The market likely overprices binary downside risk into short-dated IV; if no negative catalyst appears, sellers can harvest >7% in ~4 weeks but face asymmetric tail loss. Historical parallels: post-vaccine demand normalization produced both sharp drawdowns and rapid recoveries—meaning defined-risk selling (spreads) outperforms naked exposure. Unintended consequence: concentrated short-put books can lead to liquidity-driven assignment on gap-downs, so cap notional and keep cash reserves.

Key Decisions for Investors

• Sell-to-open cash-secured MRNA Mar 27 42 puts at bid ~3.20 (net cost basis if assigned $38.80). Size: target 1–2% AUM per leg (max aggregate 4% AUM). Exit/hedge: buy-to-close if MRNA >46 or IV rises >20% vs trade entry; if assigned, implement protective stop or hedge below $36.
• If already long MRNA, sell-to-open Mar 27 44 covered calls at ~3.35 to generate ~7.9% premium boost (11.9% total if called). Size: up to 50% of existing position; roll or unwind within 7–10 days prior to any material catalyst (earnings/trial readout).
• If unwilling to accept assignment, establish defined-risk 42/38 put spreads expiring Mar 27 (sell 42, buy 38) to cap max loss to $400 per contract width while collecting most premium. Size: 1–2% AUM equivalent, prioritize spreads over naked puts into any upcoming catalyst.
• If holding >3% position in MRNA, buy 60–90 day protective puts (e.g., 36–34 strikes) sized to cover 25–50% of position as tail insurance; trigger re-assessment if IV spikes >50% or price gaps >15% pre-market. Monitor for earnings/trial dates and set alerts for IV >120%.